Scaling cell therapy supply chains during a pandemic

Achieving donor pool sustainability and cell therapy supply chain success

5 Qualities to Seek in Your Cell Therapy Supply Chain Vendor

Considerations to help lower your cell or gene therapy logistics risk

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?

Why reliance on a small subset of donors could introduce risk for companies

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies

Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies

By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match

Overcoming challenges to cellular starting material collection

Q&A with the Be The Match BioTherapies Collection Network Liaison team